Spyre Therapeutics (SYRE) statistics

Analysts' price targets and ratings, ownership, short interest, trading figures and dates for Spyre Therapeutics, as the data feed reports them.

Analysts' mean target, 15 analysts
$123.87
32.0% above the price

The 15 analysts reported by the data feed have a mean price target for Spyre Therapeutics of $123.87, 32.0% above the $93.81 price (range $114.00–$141.00). 13.02% of the float was sold short as of Oct 30, 2026. Institutions hold 107.6% of the shares and insiders 1.5%. Source: Yahoo Finance, read Nov 17, 2026.

Key facts

Analysts' mean target
$123.87+32.0% vs price
Analysts
15
Short interest
13.02%of float, Oct 30, 2026
Short ratio
8.51 days
Institutions
107.6%
Insiders
1.54%
Beta
3.23

Figures read . Source: Yahoo Finance (quoteSummary: key statistics, financial data, recommendation trend, major holders, insider purchases, calendar events). Analysts' targets and ratings, ownership and short interest are the data feed's figures and can lag the filings and exchange reports they come from. Figures, not advice.

Analysts' consensus as reported by the data feed

15 analysts covering Spyre Therapeutics, as the data feed counts them. Price targets and ratings are other people's estimates — not facts about the company, and not advice. Distances are from the latest price the feed gave with these figures, $93.81.

Analysts' price targets for Spyre Therapeutics
Mean price target$123.8732.0% above the price (+32.0%)
Median price target$123.0031.1% above the price (+31.1%)
Highest target$141.0050.3% above the price (+50.3%)
Lowest target$114.0021.5% above the price (+21.5%)
Analysts with a target15

Ratings this month · 18 analysts

Strong buy 1(6%)Buy 16(89%)Hold 1(6%)
Analysts' ratings of Spyre Therapeutics this month, by rating
RatingAnalystsShare
Strong buy16%
Buy1689%
Hold16%
Sell00%
Strong sell00%

The feed averages these to 1.17 on its scale of 1 (strong buy) to 5 (strong sell), which it labels “strong buy”.

Who owns Spyre Therapeutics

Ownership of Spyre Therapeutics
Held by institutions107.6%407 institutions; percent of shares outstanding
Held by institutions, of the float109.3%
Held by insiders1.54%percent of shares outstanding
Shares outstanding94.97M
Float88.95Mshares available to trade
Insiders' net purchases, six months−4.13M10 purchases (761.75K shares), 15 sales (4.9M shares)

Percentages are of shares outstanding unless the row says float. Insiders' net purchases are shares bought minus shares sold by insiders, as the data feed totals their reported trades.

Short interest as reported by the data feed

Shares sold short and not yet covered, as of Oct 30, 2026. Short interest is counted twice a month, so this is not today's figure.

Short interest in Spyre Therapeutics
Shares short11.62Mas of Oct 30, 2026
Percent of float13.02%shares short ÷ float
Percent of shares outstanding12.23%shares short ÷ shares outstanding
Short ratio (days to cover)8.51shares short ÷ average daily volume

Spyre Therapeutics short interest from FINRA, with its history

Trading figures

Trading figures for Spyre Therapeutics
Beta3.23movement against the market; 1 moves with it
52-week high$110.64
52-week low$23.01
Average volume, 3 months1.26Mshares a day
Average volume, 10 days1.1Mshares a day

Questions and answers

What is the analysts' price target for Spyre Therapeutics (SYRE)?

As reported by the data feed, the mean price target of the 15 analysts covering Spyre Therapeutics is $123.87, 32.0% above the latest price of $93.81. The highest target is $141.00 and the lowest $114.00. Targets are analysts' estimates, not facts about the company and not advice.

How do analysts rate Spyre Therapeutics stock?

Of the 18 ratings the data feed reports for the current month, 1 are strong buy, 16 buy, 1 hold, 0 sell and 0 strong sell.

How many Spyre Therapeutics shares are sold short?

As reported by the data feed, 11.62M shares were sold short, 13.02% of the float as of Oct 30, 2026. At the average daily volume that is 8.51 days to cover. Short interest is reported twice a month; it is not today's figure.

Who owns Spyre Therapeutics stock?

As reported by the data feed, institutions hold 107.6% of the shares (407 institutions) and insiders 1.5%. There are 94.97M shares outstanding, of which 88.95M are in the float.

How much does Spyre Therapeutics stock move with the market?

Its beta, as reported by the data feed, is 3.23: a beta above 1 means the share has tended to move more than the market, below 1 less. Over the past 52 weeks it traded between $23.01 and $110.64.

Cite this page

Funkfolio, “Spyre Therapeutics (SYRE) statistics and analyst targets”, data as of 17 November 2026. https://funkfolio.com/stock/SYRE/statistics

Underlying data: Yahoo Finance.